During the dose-expansion phase, patients were primarily divided into five different cohorts, including those with HER-2 positive or HER-2 low-expressing advanced breast cancer, where HER-2 positive patients had previously received standard T-DM1 treatment. Here, ERBB2 is linked to breast carcinoma.